These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 31422205)

  • 1. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
    Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
    Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
    Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer.
    Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J
    Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV Meets APOBEC: New Players in Head and Neck Cancer.
    Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
    Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
    Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
    Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
    Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
    Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
    Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immune microenvironment in head and neck cancers.
    Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
    Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized cancer vaccination in head and neck cancer.
    Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
    Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.